11:47 AM
 | 
Nov 09, 2017
 |  BC Innovations  |  Emerging Company Profile

Network intelligence

Verge aims to map and drug the molecular networks causing neurological diseases

Verge Genomics Inc. has a machine learning platform, data trove and in-house wet lab geared for finding master regulators of complex neurological disease networks that traditional target-hunting approaches miss. The platform has already generated targets and compounds for its lead indication, amyotrophic lateral sclerosis, and netted the newco two pharma partners.

“The traditional pharmaceutical tools are simply not enough to crack the code on neurological diseases,” said CEO Alice Zhang. “Pharma look at single targets in diseases that are caused by hundreds of genes.”

Verge’s platform searches for disease-driving networks of molecules in nearly 65 million measurements from non-public academic databases and its own experimental results. The data encompass genetic, epigenetic, RNA and protein readouts from tens of thousands patients, including 2,000 with gene expression data in the brain or spinal cord.

The company starts by...

Read the full 663 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$85 USD
More Info >